Contrarius Group Holdings Ltd Sells 5,175,456 Shares of Intellia Therapeutics, Inc. $NTLA

Contrarius Group Holdings Ltd lowered its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 87.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 714,480 shares of the company’s stock after selling 5,175,456 shares during the quarter. Contrarius Group Holdings Ltd’s holdings in Intellia Therapeutics were worth $6,423,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Intellia Therapeutics during the third quarter valued at $30,000. Advisory Services Network LLC acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $33,000. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics during the second quarter worth approximately $26,000. Comerica Bank grew its stake in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the period. Finally, Danske Bank A S acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $50,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $13.54 on Monday. The business’s 50 day simple moving average is $13.61 and its two-hundred day simple moving average is $12.17. The firm has a market cap of $1.89 billion, a P/E ratio of -3.82 and a beta of 1.92. Intellia Therapeutics, Inc. has a 52-week low of $7.75 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the prior year, the company earned ($1.10) earnings per share. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -3.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wedbush reaffirmed a “neutral” rating and set a $12.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, May 12th. Royal Bank Of Canada lifted their price objective on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday, March 3rd. Canaccord Genuity Group lowered their price objective on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Finally, JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and an average target price of $20.25.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.